TY  - GEN
AU  - Sherrod, Charles F
AU  - Saberi, Sara
AU  - Nassif, Michael E
AU  - Claggett, Brian L
AU  - Coats, Caroline J
AU  - Garcia-Pavia, Pablo
AU  - Januzzi, James L
AU  - Lewis, Gregory D
AU  - Ma, Changsheng
AU  - Maron, Martin S
AU  - Miao, Zi Michael
AU  - Olivotto, Iacopo
AU  - Veselka, Josef
AU  - Butzner, Michael
AU  - Jacoby, Daniel L
AU  - Heitner, Stephen B
AU  - Kupfer, Stuart
AU  - Malik, Fady I
AU  - Meng, Lisa
AU  - Wohltman, Amy
AU  - Spertus, John A
PY  - 2024
UR  - https://hdl.handle.net/20.500.12105/25894
AB  - A primary goal in treating obstructive hypertrophic cardiomyopathy (oHCM) is to improve patients' health status: their symptoms, function, and quality of life. The health status benefits of aficamten, a novel cardiac myosin inhibitor, have not been...
LA  - eng
PB  - Elsevier
KW  - aficamten
KW  - hypertrophic cardiomyopathy
KW  - patient-reported outcomes
TI  - Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
TY  - research article
ER  -